Rallybio Corporation (RLYB)
NASDAQ: RLYB · Real-Time Price · USD
0.5500
-0.0151 (-2.67%)
At close: Sep 26, 2025, 4:00 PM EDT
0.5600
+0.0100 (1.82%)
After-hours: Sep 26, 2025, 7:36 PM EDT
Rallybio Employees
Rallybio had 25 employees as of December 31, 2024. The number of employees decreased by 18 or -41.86% compared to the previous year.
Employees
25
Change (1Y)
-18
Growth (1Y)
-41.86%
Revenue / Employee
$30,440
Profits / Employee
-$1,666,080
Market Cap
22.98M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25 | -18 | -41.86% |
| Dec 31, 2023 | 43 | 2 | 4.88% |
| Dec 31, 2022 | 41 | 6 | 17.14% |
| Dec 31, 2021 | 35 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RLYB News
- 2 days ago - Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study - Business Wire
- 24 days ago - Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program - Business Wire
- 7 weeks ago - Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 2 months ago - Why Is Microcap Rallybio Stock Trading Higher On Tuesday? - Benzinga
- 2 months ago - Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals - Business Wire
- 3 months ago - Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study - Business Wire
- 5 months ago - Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 5 months ago - Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference - Business Wire